Laboratory of Translational Cancer Research, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.
Indian J Med Res. 2009 Sep;130(3):247-60.
Highly effective HPV vaccines are likely to become available for use in India shortly. The availability and validation of the vaccines to prevent oncogenic HPV infection associated lesions from progressing to cancer has clearly offered a cost effective long-term strategy to reduce the cervical cancer burden, particularly for developing countries where effective screening programmes are not available. The enthusiasm for these new vaccines duly justified, are we in reality targeting the actual delinquent by prompting these vaccines in India? The answer would be no as we may not be essentially implementing a rational fool-proof vaccine program which will aid in preventing HPV-related diseases, for the simple reason that there is a lack of understanding about the underlying HPV types responsible for cervical cancer in India. Field trials involving large populations form a major part of continued analysis in understanding any disease and India is still short of such a trial as far as cervical cancer is concerned. Conducting such studies, might also act as prevention programs that will save lives and improve public health in a substantive manner.
高效的 HPV 疫苗很可能很快在印度投入使用。疫苗的供应和验证可预防致癌 HPV 感染相关病变进展为癌症，这显然为减少宫颈癌负担提供了具有成本效益的长期策略，特别是对于那些没有有效筛查计划的发展中国家。这些新疫苗的出现令人欢欣鼓舞，我们是否真的通过在印度推广这些疫苗来针对实际的罪犯？答案是否定的，因为我们可能没有真正实施一个合理、万无一失的疫苗计划，以帮助预防 HPV 相关疾病，原因很简单，我们对印度宫颈癌相关 HPV 类型缺乏了解。涉及大量人群的现场试验是继续分析任何疾病的重要组成部分，而印度在宫颈癌方面仍然缺乏这样的试验。开展这些研究也可能作为预防项目，以实质性的方式拯救生命和改善公共卫生。
